TIMOTHY J.N. WATSON, PhD
IQ Board of Directors Vice Chair (2021-2023)
IQ Board of Directors Member (2013-Present)
Executive Director/Team Leader of the GCMC Advisory Office, Pfizer, Inc.
PhD, Organic Chemistry, Ohio State University
DESCRIBE YOUR INVOLVEMENT IN IQ AND HOW HAS YOUR COMPANY BENEFITED AS A MEMBER.
I serve on the IQ Board of Directors and am responsible for the CMC Leadership Groups of IQ. My organization learned long ago that developing new science-based technologies alone is not sustainable. IQ brings together a community of companies and scientists to advance science and innovation through appropriate collaboration. When industry works together in areas like this, we make great progress and have more of an impact.
WHICH OF IQ'S ACCOMPLISHMENTS STAND OUT MOST PROMINENTLY TO YOU?
In all sincerity, I want to note that there are too many IQ accomplishments to list! However, I will highlight two:
IQ’s Co-crystals Paper. This paper had a direct impact on a project that was extremely important to patients. Without that paper, the project may not have occurred.
IQ’s Global Harmonization CMC work. This IQ work is the first direct line to ICH out of ANY organization with respect to divergence.
WHAT FACTORS INFLUENCED IQ'S GROWTH?
IQ draws scientific and technical experts. IQ is a bottom-up organization that empowers and nurtures important science-based important initiatives. Additionally, IQ is agile. It is not bureaucratic and does not have red tape. It is easy to get things done quickly.
WHAT CAN WE EXPECT FROM IQ IN THE NEXT 10 YEARS?
IQ has established itself as a leader with industry and regulators. I’d like to see IQ use that unique position and platform, including the trust it has established and superb scientific expertise it has cultivated, to continue to drive change and innovation in our industry. This is a unique time for innovation and collaboration. COVID has opened many more opportunities and IQ is well-positioned to respond.